Table 3.
Associations of patient and clinical characteristics with high-risk genomic features among estrogen receptor–borderline tumors in Carolina Breast Cancer Study phases I, II, and III
| Characteristic | Intrinsic subtype |
ROR-PT score |
||||||
|---|---|---|---|---|---|---|---|---|
| Nonbasaln = 53 | Basal-like n = 38 | Relative frequency difference* (95% CI), % | P † | Low/ medium ROR-PT n = 65 | High ROR-PTn = 24 | Relative frequency difference* (95% CI), % | P † | |
| Race | ||||||||
| White, No. (%) | 24 (60.0) | 16 (40.0) | Referent | .77 | 35 (87.5) | 5 (12.5) | Referent | .005 |
| Black, No. (%) | 29 (56.9) | 22 (43.1) | +3.1 (−17.1 to 23.3) | 30 (61.2) | 19 (38.8) | 26.2 (9.0 to 43.3) | ||
| Age, y | ||||||||
| <50, No. (%) | 34 (65.4) | 18 (34.6) | Referent | .11 | 37 (72.6) | 14 (27.5) | Referent | .79 |
| ≥50, No. (%) | 19 (48.7) | 20 (51.3) | +16.6 (−3.7 to 37.0) | 28 (73.7) | 10 (26.3) | −1.2 (−17.7 to 15.2) | ||
| Menopausal status | ||||||||
| Premenopausal, No. (%) | 31 (66.0) | 16 (34.0) | Referent | 0.12 | 33 (71.7) | 13 (28.3) | Referent | .57 |
| Postmenopausal | 22 (50.0) | 22 (50.0) | +20.6 (−10.8 to 51.9) | 32 (74.4) | 11 (25.6) | −17.8 (−52.2 to 16.7) | ||
| Grade‡ | ||||||||
| Low or intermediate, No. (%) | 22 (84.6) | 4 (15.4) | Referent | <.001 | 22 (88.0) | 3 (12.0) | Referent | .09 |
| High, No. (%) | 24 (45.3) | 29 (54.7) | +41.9 (17.7 to 66.0) | 32 (61.5) | 20 (38.5) | +23.8 (−5.8 to 53.5) | ||
*
Adjusted for age and/or race. CI = confidence interval; ER = estrogen receptor; ROR-PT = risk of recurrence, proliferation and tumor size weighted.
†
Two-sided χ2 test.
‡
Twelve participants had missing grade.